The combination of<unk>  and zidovudine is composed of two nucleotide reverse transcriptase inhibitors (NRTIs).<unk>  and zidovudine both competitively inhibit and reduce the activity of reverse transcriptase (RT) causing HIV infected cells to decrease the number of viruses in the body.<unk>  and zidovudine act as nucleoside analogs, which are substrates for the human nucleoside kinases. The initial phosphorylation step is crucial for the drug's activity, then converted into the active 5’-triphosphate form by host kinases. The drug is then incorporated to the end of the growing chain of the viral DNA causing the chain to be terminated, where nucleotides can no longer be added to the growing viral DNA. Lamividuine and zidovudine combination therapy is believed to work synergistically together to prevent mutations in the HIV virus, which can contribute to drug resistance.
Lamivudine/zidovudine
Lamivudine/tenofovir
Abacavir/lamivudine
Lamivudine/raltegravir
Doravirine/lamivudine/tenofovir
Dolutegravir/lamivudine
Lamivudine/nevirapine/zidovudine
Abacavir/lamivudine/zidovudine